RECRUITING

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

Official Title

Benefits of Oxytocin in OSA Patients Using CPAP

Quick Facts

Study Start:2019-03-04
Study Completion:2024-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03860233

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men or women 18 years of age or older.
  1. * subjects not willing to or otherwise unable to use CPAP for treatment of OSA.
  2. * Presence of other sleep disorders
  3. * Pregnant or breastfeeding women
  4. * Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study
  5. * Prisoners or subjects who are involuntarily incarcerated
  6. * Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness
  7. * Patients unable to give consent because of a language barrier, or other reason.

Contacts and Locations

Study Contact

Vivek Jain, MD
CONTACT
202-741-2237
vjain@mfa.gwu.edu

Principal Investigator

Vivek Jain, MD
PRINCIPAL_INVESTIGATOR
George Washington University
David Mendelowitz, PhD
PRINCIPAL_INVESTIGATOR
George Washington University

Study Locations (Sites)

Medical Faculty Associates
Washington, District of Columbia, 20037
United States

Collaborators and Investigators

Sponsor: Vivek Jain

  • Vivek Jain, MD, PRINCIPAL_INVESTIGATOR, George Washington University
  • David Mendelowitz, PhD, PRINCIPAL_INVESTIGATOR, George Washington University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-03-04
Study Completion Date2024-11-01

Study Record Updates

Study Start Date2019-03-04
Study Completion Date2024-11-01

Terms related to this study

Keywords Provided by Researchers

  • Continuous Positive Airway Pressure
  • CPAP
  • Oxytocin

Additional Relevant MeSH Terms

  • Sleep Apnea
  • Sleep Apnea, Obstructive